Facebook
Twitter
LinkedIn
Forward
Oral Board Review Course (2024)
Please note that the Oral Board Review Course is SOLD OUT. If you would like to be added to the waitlist, call 1-800-908-9414 or email registration@AUAnet.org.
Saturday Session- SOLD OUT!
Sunday Session- SOLD OUT!
The 2024 AUA Oral Board Review Course will take place as a live virtual course.
The purpose of the AUA Oral Board Review Course is to prepare attendees for the American Board of Urology (ABU) Certifying Examination (Part II). The course will provide attendees with valuable practice and practical preparation skills for taking the urology oral board exam. This is a highly interactive course that emulates the oral board exam given by the American Board of Urology. Attendees participate in two-75 minute mock oral exams, an Objective Structured Clinical Examination (OSCE) role play practice session, an interactive case analysis with expert examiners, take home cases and an “Ask the Experts” panel discussion with Faculty who offer tips & tricks for preparing for and successfully taking the oral examination.
In addition to experiencing mock oral exams that are realistic, attendees will also receive immediate feedback and guidance from expert oral examiners, as well as the opportunity to refine their thought process, communication skills, approach to oral exam question types, and decision-making ability.
Attendees must choose the Saturday OR Sunday Program when registering but not both.
Please select which program day you wish to be in at the time of registration. The selection is a first come basis and will be completed once you register.
Note: All course registrants will receive their final and detailed schedules via a Tips Before You Click email scheduled to arrive on or before February 2, 2024.
AUA Guarantee: This course is backed by the AUA Guarantee: If you fail the boards, then we will pay for you to retake our course. (Applicable 2023 registrants please call 1-800-908-9414)
AUA Members save 20%! For more information on membership benefits, visit www.AUAnet.org/Join.
Registration Fees
Do not miss out on this valuable preparation with additional supporting sessions for your upcoming boards!
All for one low price—Register Now Before the Course is Sold Out!
Virtual Live Course Early Bird On or Before December 29, 2023 | Virtual Course Late On or after December 30, 2023 | Oral Board Study Guide App* | |
|---|---|---|---|
| AUA Member | $1495 | $1865 | $150 |
| AUA Non-Member | $1865 | $2245 |
*Discounted Pricing on the Oral Board Study Guide App For Course Registrants Only (Regularly $299)
Target Audience
- Urologist
Learning Objectives
At the conclusion of this course, participants will be able to:
- Navigate the oral board exam format and question types successfully.
- Utilize interpersonal and communication skills resulting in effective information exchange.
- Demonstrate and refine skills to effectively manage anxiety and "exam nerves".
- Develop greater self-awareness and confidence in oral examination.
- Apply the experience gained in the AUA Oral Board Review Course to better prepare for the oral board exam.
- Practice and become familiar with the Objective Structured Clinical Examination (OSCE).
Saturday Program
Saturday, February 10, 2024, 8:30 AM – 7:00 PM EST*
*Please note that specific group assignments will be assigned and communicated via email 1-2 weeks prior to the course. Due to the complexities of the course structure, attendees may not make group requests or switch groups with any other attendee. The AUA will consider time zones to the best of our ability. Until otherwise notified, attendees should block off the entire timeframe listed above for course duration.
Includes:
- Convenient, 1 Day Virtual Format!
- 2 –75 minute Mock Exams with 1 Expert Examiner
- Interactive Case Analysis with Expert Examiner
- Objective Structured Clinical Examination (OSCE) Role Play Practice Session
- Take Home Cases
- Ask the Experts! Panel Discussion/Tips & Tricks with Faculty and ABU Process
- Special Discount Pricing of the Oral Board Study Guide APP
Sunday Program
Sunday, February 11, 2024, 8:30 AM – 7:00 PM EST*
*Please note that specific group assignments will be assigned and communicated via email 1-2 weeks prior to the course. Due to the complexities of the course structure, attendees may not make group requests or switch groups with any other attendee. The AUA will consider time zones to the best of our ability. Until otherwise notified, attendees should block off the entire timeframe listed above for course duration.
Includes:
- Convenient, 1 Day Virtual Format!
- 2 –75 minute Mock Exams
- Interactive Case Analysis with Expert Examiner
- Objective Structured Clinical Examination (OSCE) Role Play Practice Session
- Take Home Cases
- Ask the Experts! Panel Discussion/Tips & Tricks with Faculty and ABU Process
- Special Discount Pricing of the Oral Board Study Guide APP
Faculty Disclosures will be posted here prior to the course.
Education Council Disclosures
Education Council Disclosures.pdf
COI Review Work Group Disclosures
COI Review Work Group Disclosures.pdf
Faculty Disclosures
Name | Company Name | Relationship Type | End Date |
Babaian, Kara N. | Janssen | Scientific Study or Trial | 10/19/2022 |
Badani, Ketan | Nothing relevant to disclose |
|
|
Badlani, Gopal | Lithotripsy group : Piedmont stone & physcian disc | Other-Limited partner | Current |
Badlani, Gopal | AAGUS | Leadership Position | Current |
Badlani, Gopal | Neotract | Consultant or Advisor | Current |
Badlani, Gopal | Urology times | Health Publishing | Current |
Badlani, Gopal | Procept | Scientific Study or Trial | Current |
Badlani, Gopal | Olympus | Scientific Study or Trial | Current |
Badlani, Gopal | Boston Scientific | Scientific Study or Trial | Current |
Baker, Karen C. | FrameFertility | Consultant or Advisor | Current |
Baker, Karen C. | Diviner | Other-Forecaster | Current |
Baker, Karen C. | Ysios Capital | Consultant or Advisor | Current |
Bayne, Christopher | Journal of Pediatric Urology | Health Publishing | Current |
Bayne, Christopher | Vidscrip | Consultant or Advisor | Current |
Carroll, Peter Robert | NIH | Scientific Study or Trial | Current |
Carroll, Peter Robert | Nutcracker Therapeutics | Consultant or Advisor | Current |
Carroll, Peter Robert | Francis Medical | Consultant or Advisor | Current |
Carroll, Peter Robert | Nutcracker Therapeutics | Consultant or Advisor | Current |
Carroll, Peter Robert | Insigtec | Consultant or Advisor | 10/23/2023 |
Carroll, Peter Robert | Biopharmcommunications | Health Publishing | 09/06/2023 |
Carroll, Peter Robert | Francis Medical | Consultant or Advisor | 10/23/2022 |
Carroll, Peter Robert | alessa | Consultant or Advisor | Current |
Chi, Thomas | Boston Scientific Corporation | Consultant or Advisor | Current |
Chi, Thomas | Auris | Consultant or Advisor | Current |
Chi, Thomas | Bard Medical | Consultant or Advisor | Current |
Chi, Thomas | Dornier | Consultant or Advisor | Current |
Chi, Thomas | Cook | Consultant or Advisor | Current |
Chi, Thomas | Lumenis | Consultant or Advisor | Current |
Chi, Thomas | Applaud | Scientific Study or Trial | 03/31/2023 |
Chi, Thomas | Vibronix | Consultant or Advisor | Current |
Chi, Thomas | Mendaera | Consultant or Advisor | Current |
Chi, Thomas | UroViu | Consultant or Advisor | Current |
Chi, Thomas | Calyxo | Consultant or Advisor | Current |
Clifton, Marisa M. | Nothing relevant to disclose |
|
|
Comiter, Craig Vance | zenflow | Scientific Study or Trial | Current |
Comiter, Craig Vance | Neuspera | Scientific Study or Trial | Current |
Comiter, Craig Vance | BE technologies | Scientific Study or Trial | Current |
Comiter, Craig Vance | coloplast | Scientific Study or Trial | Current |
Comiter, Craig Vance | procept | Consultant or Advisor | Current |
Dall'Era, Marc Arnaldo | MDxHealth | Scientific Study or Trial | 04/26/2022 |
Dall'Era, Marc Arnaldo | Photocure | Consultant or Advisor | 04/26/2022 |
Dall'Era, Marc Arnaldo | Janssen | Scientific Study or Trial | Current |
Dall'Era, Marc Arnaldo | Tempus | Scientific Study or Trial | Current |
Dall'Era, Marc Arnaldo | Prostatype Genomics | Consultant or Advisor | 09/01/2023 |
Downs, Tracy M. | Nothing relevant to disclose |
|
|
Droller, Michael J. | Miscellaneous legal expert consultant | Consultant or Advisor | Current |
Droller, Michael J. | Elsevier Inc. (Urologic Oncology: Seminars and Ori | Leadership Position | Current |
Eisner, Brian Howard | Boston Scientific | Consultant or Advisor | Current |
Eisner, Brian Howard | Kalera Medical | Intellectual Property | Current |
Eisner, Brian Howard | Sonomotion | Consultant or Advisor | Current |
Eisner, Brian Howard | Allena Pharmaceuticals | Consultant or Advisor | Current |
Eisner, Brian Howard | Dr. Arnies LLC | Intellectual Property | Current |
Eisner, Brian Howard | Auris Robotics | Consultant or Advisor | Current |
Eisner, Brian Howard | Olympus | Consultant or Advisor | Current |
Eisner, Brian Howard | Cook Urological | Consultant or Advisor | Current |
Eisner, Brian Howard | AMBU | Consultant or Advisor | Current |
Giel, Dana W. | Nothing relevant to disclose |
|
|
Gonzalgo, Mark | Clearcyte Diagnostics | Consultant or Advisor | Current |
Gonzalgo, Mark | Organicell | Consultant or Advisor | Current |
Gupta, Mantu | Cook Urological | Meeting Participant or Lecturer | Current |
Gupta, Mantu | Olympus | Consultant or Advisor | Current |
Gupta, Mantu | Boston Scientific Inc | Meeting Participant or Lecturer | Current |
Gupta, Mantu | Retrophin Inc | Meeting Participant or Lecturer | 06/01/2022 |
Gupta, Mantu | Applaud Medical | Scientific Study or Trial | 02/20/2023 |
Hampson, Lindsay A. | Boston Scientific | Consultant or Advisor | 08/15/2022 |
Ivancic, Vesna | Nothing relevant to disclose | Nothing relevant to disclose | Nothing relevant to disclose |
Jacobs, Micah A. | Nothing relevant to disclose | Nothing relevant to disclose | Nothing relevant to disclose |
Johnson, Brett A. | Ambu Inc | Scientific Study or Trial | 01/01/2023 |
Johnson, Brett A. | Coloplast USA | Consultant or Advisor | 10/01/2023 |
Kieran, Kathleen | Status: Nothing to disclose |
|
|
Konety, Badrinath R. | Photocure | Consultant or Advisor | 01/01/2023 |
Konety, Badrinath R. | Astrin Biosciences | Stock Option | Current |
Konety, Badrinath R. | Styx Biotechnology | Stock Option | Current |
Konety, Badrinath R. | Asieris Inc | Consultant or Advisor | Current |
Konety, Badrinath R. | Ferrying Inc | Consultant or Advisor | 04/01/2024 |
Konety, Badrinath R. | Illumina Inc | Consultant or Advisor | 05/10/2024 |
Konety, Badrinath R. | Abbott Inc | Consultant or Advisor | Current |
Konety, Badrinath R. | Bladder Cancer | Other-editorial board | Current |
Konety, Badrinath R. | Translational Andrology Urology | Other-member editorial board | Current |
Konety, Badrinath R. | American College of Surgeons | Other-member | Current |
Konety, Badrinath R. | Society of Urologic Oncology | Other-member | Current |
Konety, Badrinath R. | American Society of Clinical Oncology | Other-member | Current |
Masterson, Timothy A. | SUO Fellowship Committee Chair & Institutional PD | Leadership Position | Current |
Masterson, Timothy A. | Urologic Oncology journal | Health Publishing | Current |
Mayer, Wesley A. | Applaud Medical | Scientific Study or Trial | Current |
Mayer, Wesley A. | Novo Nordisk | Consultant or Advisor | Current |
McAchran, Sarah Elizabeth | Pfizer | Investment Interest | Current |
Mehta, Akanksha | Posterity Health | Other-Advisory Board Member | Current |
Merrill, Suzanne B. | Photocure | Consultant or Advisor | Current |
Munver, Ravi | Boston Scientific | Meeting Participant or Lecturer | 12/31/2022 |
Munver, Ravi | Urogen, Inc | Meeting Participant or Lecturer | Current |
Munver, Ravi | PROCEPT BioRobotics | Consultant or Advisor | Current |
Munver, Ravi | Boston Scientific | Consultant or Advisor | Current |
Ost, Michael C. | Nothing relevant to disclose |
|
|
Peterson, Andrew Charles | BSCI: American Medical Systems INC | Consultant or Advisor | Current |
Peterson, Andrew Charles | BSCI: Boston Scientific | Scientific Study or Trial | Current |
Peterson, Andrew Charles | BSCI: Boston Scientific | Other-Course instructor | Current |
Polascik, Thomas James | angiodynamics | Consultant or Advisor | 07/17/2023 |
Polascik, Thomas James | Frances Medical | Consultant or Advisor | 07/17/2023 |
Polascik, Thomas James | Galvanize | Consultant or Advisor | 07/17/2023 |
Polascik, Thomas James | Merck | Scientific Study or Trial | 07/17/2023 |
Polascik, Thomas James | Janssen | Scientific Study or Trial | 07/17/2023 |
Polascik, Thomas James | Astellas | Scientific Study or Trial | 07/17/2023 |
Polascik, Thomas James | Wasatch | Consultant or Advisor | 07/17/2023 |
Porten, Sima Prabodh | Photocure | Scientific Study or Trial | Current |
Porten, Sima Prabodh | Coloplast | Consultant or Advisor | 10/31/2022 |
Porten, Sima Prabodh | Stryker | Consultant or Advisor | Current |
Porten, Sima Prabodh | AstraZeneca | Consultant or Advisor | Current |
Porten, Sima Prabodh | Pacific Edge | Consultant or Advisor | Current |
Psutka, Sarah P. | Bladder Cancer Advocacy Network | Other-Research Grant Funding | Current |
Psutka, Sarah P. | Janssen | Scientific Study or Trial | Current |
Psutka, Sarah P. | European Urology | Leadership Position | Current |
Psutka, Sarah P. | Bladder Cancer | Other-Editorial Board | Current |
Psutka, Sarah P. | Medtronic | Other-Honoraria supporting travel to USANZ (AUA Lecture) | 06/29/2022 |
Psutka, Sarah P. | ImmunityBio | Consultant or Advisor | Current |
Ramasamy, Ranjith | Coloplast | Consultant or Advisor | Current |
Ramasamy, Ranjith | Boston Scientific | Consultant or Advisor | Current |
Ramasamy, Ranjith | Endo Pharmaceuticals | Consultant or Advisor | Current |
Ramasamy, Ranjith | Acerus Pharmaceuticals | Scientific Study or Trial | 01/17/2023 |
Rastinehad, Art R. | Philips, Inc | Scientific Study or Trial | Current |
Rastinehad, Art R. | NanoSpectra Biopsciences | Consultant or Advisor | Current |
Riley, Julie M. | Boston Scientific | Consultant or Advisor | Current |
Schlomer, Bruce J. | Nothing relevant to disclose |
|
|
Shridharani, Anand | Coloplast Inc | Consultant or Advisor | Current |
Streeper, Necole M. | NIH | Scientific Study or Trial | Current |
Terlecki, Ryan Patrick | Boston Scientific | Consultant or Advisor | Current |
Terlecki, Ryan Patrick | U.S. Department of Defense | Scientific Study or Trial | Current |
Woo, Lynn L. | Nothing relevant to disclose |
|
|
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
AUA ACCREDITATION INFORMATION
ACCREDITATION:
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION:
The American Urological Association designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
OTHER LEARNERS:
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:
- Peer review for valid, evidence-based content by the AUA COI Review Work Group.
- Attestation that clinical recommendations are evidence-based and free of commercial bias.
- Introduction of a debate format (point-counterpoint)
- Inclusion of moderated panel discussion with unbiased moderator
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Divestiture of the relationship by faculty
- Recusal from controlling relevant aspects of planning
- Selection of alternative faculty for specific topic
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Price
Attendees must choose the Saturday OR Sunday Program when registering but not both.
Please select which program day you wish to be in at the time of registration. The selection is a first come basis and will be completed once you register.
The Oral Board Study Guide App must be added to registration from this page for purchase.
AUA Members save 20%! For more information on membership benefits, visit www.AUAnet.org/Join.
Registration Fees
Do not miss out on this valuable preparation with additional supporting sessions for your upcoming boards!
All for one low price—Register Now Before the Course is Sold Out!
Virtual Live Course Early Bird On or Before December 29, 2023 | Virtual Course Late On or after December 30, 2023 | Oral Board Study Guide App* | |
|---|---|---|---|
| AUA Member | $1495 | $1865 | $150 |
| AUA Non-Member | $1865 | $2245 |
*Discounted Pricing on the Oral Board Study Guide App Only For Course Registrants (Regularly $299)
Cancellation Policy
Live Virtual Course: An administrative fee of 15% is assessed if registration is cancelled up to six weeks prior to the course. If registration is cancelled four to six weeks from the course, the cancellation fee is 50% of the registration fee paid. No registration fees will be refunded less than four weeks prior to the course.
Registration Transfer: Customers switching from an option of lesser value to a higher value will be required to pay the difference in cost between the two options. Switching to an option of lesser value from a higher value must be made no later than six weeks prior to the course and will be subject to an administrative fee of 15% of the cost of the course from which they are transferring. Transfer of registration from a higher value option to an option of lesser value past six weeks prior to the course will not receive a refund.
Cancellations must be made in writing. Requests may be made via mail or fax to 410-689-3912. Questions? Call 1-800-908-9414 or email registration@AUAnet.org.
AUA Education & Research reserves the right to cancel this course if a minimum enrollment is not reached before December 29, 2023. If AUA Education & Research cancels this course, registration fees will be refunded in full and notification will be sent by January 12, 2024.
ATTENDEE INFORMATION & POLICIES
AUA Anti-Harassment Policy: AUA Commitment: AUA is committed to providing a safe and productive meeting environment that fosters open dialogue and the exchange of scientific ideas and is free of harassment and discrimination. All meeting participants are expected to behave professionally and treat others with respect, follow venue rules, and alert AUA staff or security of any dangerous situations or anyone in distress.
Reporting Harassment: It is the policy of the AUA that all meeting participants will enjoy an environment free from discrimination, harassment or retaliation. Harassing behavior by meeting participants will not be tolerated. If an individual experiences or witnesses harassment, he or she should contact Janet Skorepa, AUA EVP, at jskorepa@AUAnet.org or Maureen E. Cones, Esq., AUA General Counsel, at mcones@auanet.org or use a venue phone and ask for security if he or she feels unsafe. All complaints will be treated seriously and responded to promptly.
The AUA reserves the right to take any action deemed necessary and appropriate, including refusing or revoking the registration of any individual, without refund, as long as such refusal is consistent with applicable law and AUA policy.
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association (AUA).
Consent to Use of Photographic Images: Registration and attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities.
Audio, Video, Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the AUA.
Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, a written request should be submitted at least one month in advance. For additional assistance with your request please call 1-800-908-9414.